Wegovy has become one of the most well-known prescription weight loss medications in the UK, backed by extensive clinical trial data and a growing body of real-world evidence. For patients in Northern Ireland, however, the challenge has not been whether Wegovy works. It has been figuring out how to actually access it.
NHS availability of Wegovy in Northern Ireland remains extremely limited. Specialist weight management services across the Health and Social Care Trusts have long waiting lists, and GP prescribing of GLP-1 medications for weight loss is uncommon. For most NI patients, private prescription through an online clinic has become the practical route to treatment.
This guide covers everything you need to know about Wegovy in Northern Ireland: what it is, how it works, who is eligible, the dosing schedule, expected results, side effects, costs, and how to get started through an RQIA-regulated service that delivers to your door.
What Is Wegovy?
Wegovy is the brand name for semaglutide 2.4 mg, a prescription medication manufactured by Novo Nordisk. It is specifically licensed for weight management in adults who meet certain clinical criteria. While semaglutide is also the active ingredient in Ozempic (used for type 2 diabetes at lower doses), Wegovy is formulated specifically for weight loss at a higher dose and is licensed accordingly.
Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. The injection is given just under the skin, typically in the abdomen, upper thigh, or upper arm. The pen device is designed for simple self-administration at home, and most patients become comfortable with the process after the first one or two injections.
How Semaglutide Works for Weight Loss
Wegovy is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone that your body naturally produces in response to eating. It plays several critical roles in appetite and metabolism:
- Appetite reduction: GLP-1 acts on areas of the brain involved in hunger and satiety, reducing your desire to eat and helping you feel satisfied with smaller portions.
- Delayed gastric emptying: It slows the rate at which food leaves your stomach, extending the feeling of fullness after meals.
- Blood sugar regulation: GLP-1 stimulates insulin release in response to food and suppresses glucagon, helping to stabilise blood sugar levels and reduce the spikes and crashes that can trigger cravings.
- Reward pathway modulation: Emerging research suggests that GLP-1 agonists may also reduce the reward value of food, decreasing the psychological pull of high-calorie foods and reducing food-related preoccupation.
Wegovy amplifies these natural effects by providing semaglutide at a dose that produces sustained, clinically significant appetite reduction. Patients typically describe a quieting of food noise, fewer cravings, and a natural ability to stop eating when satisfied, something that willpower alone could never reliably achieve.
Wegovy Availability in Northern Ireland
Understanding the current availability landscape in Northern Ireland is important, because it explains why most NI patients access Wegovy through private clinics rather than the NHS.
NHS Availability in NI
Despite NICE recommending semaglutide for weight management, NHS prescribing of Wegovy in Northern Ireland is very limited. The reasons are multifaceted:
- Specialist service capacity: Tier 3 weight management services, where these medications would typically be initiated, are scarce across Northern Ireland. Waiting lists in some Health and Social Care Trust areas extend to 12 months or more.
- Commissioning and funding: Decisions about which medications are funded and available on the NHS in Northern Ireland do not always follow the same timeline as England. The commissioning process can lag behind NICE guidance.
- Supply considerations: Global supply constraints for semaglutide have at various points affected availability, though the situation has improved substantially.
- GP prescribing limitations: Most GPs in Northern Ireland do not initiate GLP-1 medications for weight management. This is typically considered a specialist-initiated treatment, which creates a bottleneck given the limited number of specialist services.
In practical terms, if you visit your GP in Belfast, Derry, Lisburn, or anywhere else in Northern Ireland and ask for Wegovy, you are very unlikely to receive a prescription through NHS channels. Your GP may refer you to a specialist weight management service, but the waiting time is likely to be substantial.
Private Prescription: The Practical Route
For the majority of patients in Northern Ireland who want to access Wegovy, private prescription through a regulated online clinic is the most accessible and timely option. This route allows you to undergo a medical assessment, receive a prescription from a qualified clinician, and have your medication delivered to your home, all without the waiting lists associated with NHS services.
Who Is Eligible for Wegovy?
Wegovy is prescribed for adults who meet specific clinical criteria, based on guidelines from NICE and the medication’s licensing terms:
- BMI of 30 or higher (classified as obesity), or
- BMI of 27 or higher with at least one weight-related health condition, such as:
- Type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- High cholesterol (dyslipidaemia)
- Obstructive sleep apnoea
- Polycystic ovary syndrome (PCOS)
- Non-alcoholic fatty liver disease
- Cardiovascular disease
Additional eligibility requirements include:
- Being aged 18 or over
- Having attempted dietary and lifestyle changes without achieving adequate weight loss
- No contraindications to semaglutide (see the section below on who should not take Wegovy)
- Not currently pregnant, breastfeeding, or planning pregnancy
If you are unsure whether you qualify, you can check your eligibility in minutes by completing our free online questionnaire.
Wegovy Dosing Schedule
Wegovy uses a carefully structured dose escalation schedule. You do not start at the full therapeutic dose. Instead, you begin at a low dose and increase gradually over 16 weeks, which helps your body adjust and minimises gastrointestinal side effects.
| Phase | Dose | Duration |
|---|---|---|
| Month 1 | 0.25 mg | 4 weeks |
| Month 2 | 0.5 mg | 4 weeks |
| Month 3 | 1.0 mg | 4 weeks |
| Month 4 | 1.7 mg | 4 weeks |
| Month 5 onwards | 2.4 mg | Maintenance dose |
The 16-week titration period serves an important clinical purpose. By increasing the dose gradually, your body has time to adapt to the effects of semaglutide, and the gastrointestinal side effects that are most common (nausea, in particular) are significantly reduced compared to starting at a higher dose immediately.
Some patients may find that a dose below 2.4 mg provides sufficient appetite control and weight loss. In these cases, your prescribing clinician may recommend staying on a lower maintenance dose. Conversely, if you tolerate the medication well and are not achieving the desired results, a higher dose may be considered, as a newer 7.2 mg formulation has shown even greater weight loss in clinical trials.
Expected Weight Loss with Wegovy
The clinical evidence for Wegovy comes from the extensive STEP (Semaglutide Treatment Effect in People with obesity) trial programme. Here are the key results:
STEP 1 Trial (Standard 2.4 mg Dose)
- Participants lost an average of approximately 14.9% of their body weight over 68 weeks
- One-third of participants lost 20% or more of their body weight
- For a patient starting at 100 kg, this equates to approximately 15 kg (about 2 stone 5 lbs) of weight loss
STEP 8 Trial (Higher 7.2 mg Dose)
- The newer, higher dose achieved approximately 20.7% body weight loss
- Nearly half of participants lost 20% or more of their body weight
- This dose narrows the gap between Wegovy and Mounjaro in terms of average weight loss
What This Means in Practical Terms
For patients in Northern Ireland starting Wegovy at a typical body weight, the results translate to meaningful, life-changing weight loss:
- Starting weight 90 kg (14 stone 2 lbs): Expected loss of approximately 13.4 kg (2 stone 2 lbs)
- Starting weight 105 kg (16 stone 7 lbs): Expected loss of approximately 15.6 kg (2 stone 6 lbs)
- Starting weight 120 kg (18 stone 13 lbs): Expected loss of approximately 17.9 kg (2 stone 12 lbs)
Beyond the weight loss itself, clinical trial participants consistently reported improvements in blood pressure, blood sugar control, cholesterol levels, waist circumference, and quality of life. The SELECT cardiovascular outcomes trial also demonstrated that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20%, even in patients with minimal weight loss. This cardiovascular benefit is one of the distinguishing features of Wegovy compared to other weight loss medications.
Side Effects and How to Manage Them
Understanding the potential side effects of Wegovy before you start treatment helps you manage them effectively if they occur. The majority of side effects are gastrointestinal and tend to be temporary.
Common Side Effects
- Nausea: The most frequently reported side effect, affecting up to 44% of patients in clinical trials. It is usually mild to moderate, worst during dose increases, and improves as your body adjusts. Eating smaller meals, avoiding fatty foods, and eating slowly can help.
- Diarrhoea: Reported by approximately 30% of patients. Usually self-limiting and most common during the first few weeks at a new dose. Staying well hydrated is important.
- Constipation: Affects some patients as the medication slows digestive motility. Adequate fluid intake, fibre-rich foods, and gentle physical activity can help.
- Vomiting: Less common than nausea but can occur, particularly during dose titration. If vomiting is persistent, contact your prescribing clinician, as a slower dose titration may be appropriate.
- Abdominal pain: Mild stomach discomfort or bloating is relatively common in the early weeks.
- Headache: Some patients report headaches, particularly in the first week or two.
- Fatigue: Feeling tired is common during dose increases and usually resolves within a few days.
- Injection site reactions: Mild redness or tenderness at the injection site. Rotating between the abdomen, thigh, and upper arm helps.
Strategies for Managing Side Effects
Most side effects can be managed with simple practical steps:
- Eat smaller, more frequent meals rather than large portions
- Avoid fatty, fried, and very rich foods, especially during dose increases
- Stay well hydrated with water and clear fluids
- Eat slowly and stop eating when you feel comfortably satisfied, not full
- Avoid lying down immediately after eating
- Take your injection at a consistent time each week
Rare but Serious Side Effects
- Pancreatitis: Rare. Severe persistent abdominal pain, particularly if radiating to the back, requires immediate medical attention.
- Gallbladder disease: Rapid weight loss from any cause can increase gallstone risk. Report persistent upper right abdominal pain to your clinician.
- Allergic reactions: Very rare. Signs include swelling of the face, lips, or throat, difficulty breathing, or severe rash. Seek emergency care if these occur.
- Thyroid tumours: In animal studies, semaglutide caused thyroid tumours. While this has not been confirmed in humans, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
Our clinical team monitors patients throughout treatment and is available to provide guidance on side effect management. If side effects are intolerable at any point, your dose can be adjusted or the titration schedule slowed down.
Cost of Wegovy in Northern Ireland
As Wegovy is primarily available through private prescription in Northern Ireland, understanding the costs involved helps you plan and budget for treatment. Monthly costs vary between providers and can change as wholesale medication prices fluctuate.
At the time of writing, monthly costs for Wegovy typically fall within the following ranges:
- 0.25 mg (month 1): From approximately £130 per month
- 0.5 mg (month 2): From approximately £140 per month
- 1.0 mg (month 3): From approximately £160 per month
- 1.7 mg (month 4): From approximately £190 per month
- 2.4 mg (maintenance): From approximately £220 to £250 per month
When evaluating costs, consider what is included in the price. At Evernu, our pricing covers the medication, clinical assessment, ongoing monitoring, and support. Some providers advertise lower headline prices but charge separately for consultations, follow-up appointments, and support, which can significantly increase the total cost of treatment.
Many patients find that the cost of effective medical weight loss treatment compares favourably to the accumulated spending on diet programmes, meal replacement products, gym memberships, supplements, and other approaches that did not deliver lasting results. The difference is that Wegovy has Level 1 clinical evidence demonstrating its effectiveness.
How Wegovy Compares to Mounjaro
Wegovy and Mounjaro (tirzepatide) are the two leading prescription weight loss medications available in Northern Ireland. Patients often ask which one is better, and the honest answer is that it depends on your individual circumstances.
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Average weight loss | ~15% (standard dose), ~20.7% (higher dose) | ~15% to 22.5% depending on dose |
| Cardiovascular benefit | Proven 20% reduction in major CV events | Cardiovascular trials ongoing |
| Track record | Longer established | Newer to market |
| Titration period | 16 weeks to maintenance dose | Variable, typically 20+ weeks to higher doses |
| Administration | Once-weekly injection | Once-weekly injection |
When Wegovy May Be the Better Choice
- Cardiovascular concerns: If you have existing cardiovascular risk factors, Wegovy’s proven ability to reduce major cardiovascular events is a significant advantage. The SELECT trial data is robust and has led to semaglutide being recognised not just as a weight loss medication but as a cardiovascular protective agent.
- Preference for established safety data: Wegovy has been on the market longer and has a more extensive body of real-world safety data.
- First-time GLP-1 use: Some clinicians prefer to start patients on semaglutide first, as it has a longer established track record in the UK.
When Mounjaro May Be the Better Choice
- Maximum weight loss is the priority: Mounjaro’s dual mechanism tends to produce slightly higher average weight loss at the highest doses.
- Previous insufficient response to GLP-1 alone: If a patient has tried semaglutide and not achieved adequate results, the additional GIP pathway may provide further benefit.
- Insulin resistance or type 2 diabetes: The dual mechanism may offer additional metabolic benefits for patients with significant insulin resistance.
Your prescribing clinician will discuss both options with you and recommend the medication most suited to your individual clinical profile. For a comprehensive comparison, see our Wegovy vs Mounjaro guide.
Who Should Not Take Wegovy
Wegovy is not suitable for everyone. Contraindications include:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known allergy to semaglutide or any excipients in Wegovy
- Current pregnancy, breastfeeding, or planning to become pregnant within 2 months (semaglutide should be stopped at least 2 months before planned conception)
- History of pancreatitis
- Severe renal impairment (requires careful assessment)
- Severe gastrointestinal conditions such as gastroparesis or inflammatory bowel disease (requires specialist assessment)
These contraindications are assessed as part of the medical questionnaire and clinical review process. Our clinicians will not prescribe Wegovy if it is not safe for you, and will discuss alternative options if applicable.
RQIA Regulation: Your Protection as an NI Patient
The growth of online prescribing services has been overwhelmingly positive for patient access, but it has also attracted providers of varying quality and legitimacy. As a patient in Northern Ireland, the single most important thing you can check when choosing a weight loss clinic is whether they are properly regulated.
In Northern Ireland, healthcare services are regulated by the RQIA (Regulation and Quality Improvement Authority). Evernu is RQIA-regulated, which provides you with several important protections:
- Qualified prescribers: All clinical decisions are made by registered, qualified healthcare professionals
- Genuine medication: Prescriptions are dispensed by registered pharmacies using authorised pharmaceutical supply chains
- Clinical governance: Standardised assessment protocols, safety monitoring, and quality assurance
- Accountability: Regulatory oversight, inspection, and a formal complaints process
- Data protection: Your medical information is handled in compliance with UK data protection law
This is not a marketing badge. It is a legal and regulatory framework that exists to protect patients. When your health is at stake, choosing a regulated provider is not optional. It is essential.
How to Get Started with Wegovy in Northern Ireland
If you live anywhere in Northern Ireland and are interested in Wegovy for weight management, here is how to begin:
- Check your eligibility: Complete our free online medical questionnaire. It takes around 10 minutes and covers your medical history, current medications, BMI, and weight loss goals.
- Clinical review: A prescribing clinician reviews your information, assesses your suitability for Wegovy, and determines the appropriate treatment plan.
- Prescription and delivery: If approved, your Wegovy pen is prescribed, dispensed by a registered pharmacy, and delivered to your home in temperature-controlled packaging. We deliver across all of Northern Ireland, including Belfast, Derry/Londonderry, Lisburn, Newry, Bangor, Craigavon, Ballymena, Omagh, Enniskillen, Coleraine, Dungannon, and all surrounding areas.
- Ongoing monitoring: Regular check-ins with our clinical team to monitor your progress, manage any side effects, and adjust your dose through the titration schedule and beyond.
Our remote consultation model means that you receive the same quality of specialist weight management care regardless of where you live in Northern Ireland. Whether you are in central Belfast or rural County Fermanagh, your experience and the clinical standards applied to your care are identical.
Visit our weight loss treatment page for more information, or start your free eligibility check now. If you would like to explore your options further, our blog has detailed guides on all aspects of GLP-1 treatment, including comparisons, side effect management, and maintaining your results long-term.
Effective weight management is not about willpower. It is about giving your body the right support. If diet and exercise alone have not been enough, medical treatment with Wegovy may be the next step that makes the difference.
